Clinical trials: Seasonal Influenza
- Condition Seasonal Influenza
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Seasonal Influenza
Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age
This study will evaluate the safety and immunogenicity in healthy children and adolescents after one or two IM dose(s) of trivalent subunit inactivated flu vaccine.
- Trial name
- NCT01209780
- Testing
- TIV, TIVf, Comparator TIV
- Where
- 13 sites in Colombia, Mexico and 2 more
- Volunteers
- 3,116 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Seasonal Influenza
A Clinical Trial of Quadrivalent Influenza Vaccine in Children Aged 3-8 Years Old
This is an open-label, randomized and controlled phase Ⅳ clinical trial of quadrivalent influenza vaccine manufactured by Sinovac Biotech Co.
- Trial name
- NCT04997239
- Testing
- Two doses of quadrivalent influenza vaccine, One dose of quadrivalent influenza vaccine
- Where
- China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza
Tolerability and Safety Study of FLUVAL P Monovalent Influenza Vaccine in Children
To determine the tolerability and safety of FLUVAL P monovalent influenza vaccine in children.
- Trial name
- NCT01100294
- Testing
- Vaccination with FLUVAL P
- Where
- Hungary
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza
Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTM
This study is designed to assess the immunogenicity, reactogenicity and safety following vaccination with GSK Biologicals' FluarixTM vaccine in children who have previously been vaccinated with one dose of PandemrixTM at the age…
- Trial name
- NCT01190215
- Testing
- FluarixTM, HavrixTM Junior (in subjects of 15 years old or below) or HavrixTM (in subjects above 15 years old)
- Where
- Finland
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactivated Split Influenza Vaccine in Healthy Korea Children
The purpose of this study is to evaluate the safety and immunogenicity of IL-YANG Inactivated Split Influenza Vaccine (IL-YANG FLU Vaccine Prefilled Syringe INJ.) administered as a single intramuscular injection.
- Trial name
- NCT02263131
- Testing
- IL-YANG FLU Vaccine Prefilled Syringe INJ., VAXIGRIP Prefilled Syringe INJ.
- Volunteers
- 416 people, healthy volunteers welcome
- Sponsor
- Il-Yang Pharm. Co., Ltd.
Seasonal Influenza
Evaluating the Safeness of Trivalent Subunit Inactivated Influenza Vaccines in Preventing Flu on Vietnamese Volunteers
The present study will evaluate the safety in healthy people aged 1- 45 years (male and female) after single intramuscular (IM) dose of trivalent subunit inactivated influenza vaccine till the 30-days follow-up period.
- Trial name
- NCT01123954
- Testing
- Seasonal flu vaccine
- Where
- Vietnam
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza, Human
Post-authorisation Passive Enhanced Safety Surveillance of Seasonal Influenza Vaccines: Pilot Study in England
This pilot study, to be conducted in the 2017/2018 influenza season, is a safety surveillance study using passive surveillance enhanced with a reporting card system to report adverse events of interest (AEIs) after Flu…
- Trial name
- NCT03278067
- Testing
- Enhanced vaccine safety surveillance
- Where
- United Kingdom
- Volunteers
- 23,939 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children 6 to 35 Months of Age
The purpose of this study is to investigate the immunogenicity, reactogenicity and safety of the new influenza vaccine GSK2282512A (FLU-Q-QIV) and compare its activity to the marketed vaccine Fluarix® (TIV) in young children 6 to…
- Trial name
- NCT01711736
- Testing
- Quadrivalent influenza GSK2282512A vaccine, Fluarix
- Where
- 8 sites in Canada, Dominican Republic and 1 more
- Volunteers
- 606 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Human Influenza
Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection for Children and Adolescents
Immunogenicity and Tolerability Study of Fluval AB Novo Suspension for Injection (trivalent, seasonal influenza vaccine, active ingredient content: 6 μg HA/strain/0.5 ml) for Children and Adolescents.
- Trial name
- NCT02387294
- Testing
- Vaccination with Fluval AB Novo suspension for injection, half dose of a single intramuscular dose (0.25 ml), Vaccination with Fluval AB Novo suspension for injection, single intramuscular dose (0.5 ml)
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Influenza
A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Children
This study is designed to test the immunogenicity and safety of an investigational influenza vaccine, in children compared to two other influenza vaccines.
- Trial name
- NCT01198756
- Testing
- Quadrivalent seasonal influenza vaccine GSK2282512A, Fluarix™ VB, Fluarix™ YB
- Where
- 33 sites in United States, Canada and 3 more
- Volunteers
- 3,109 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345
The purpose of this study is to assess the safety and immunogenicity of GSK Biologicals' investigational vaccine GSK2321138A in children who previously participated in study 115345 (FLU D-QIV-004 PRI) (NCT01439360).
- Trial name
- NCT01702454
- Testing
- Fluarix Quadrivalent
- Where
- 33 sites in Czechia, Poland and 2 more
- Volunteers
- 470 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Seasonal Influenza, Cough
Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected Influenza
This is a Phase 3, open-label, randomized study of the antiviral activity, safety, and tolerability of intravenous Peramivir in hospitalized subjects with confirmed or suspected influenza infection.
- Conditions
- Seasonal Influenza, Cough, Sore Throat, Nasal Congestion
- Trial name
- NCT00957996
- Testing
- Peramivir
- Where
- 110 sites in United States, Australia and 4 more
- Volunteers
- 234 people
- Sponsor
- BioCryst Pharmaceuticals
Influenza
An Efficacy Study of GlaxoSmithKline (GSK) Biologicals' Candidate Influenza Vaccine GSK2321138A in Children
The purpose of this study is to evaluate the efficacy, immunogenicity and safety of GSK Biologicals' influenza candidate vaccine GSK2321138A when compared to non-influenza vaccine comparators in children 6 to 35 months of age.
- Trial name
- NCT01439360
- Testing
- Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A, Havrix Junior, Prevenar 13
- Where
- 103 sites in Bangladesh, Belgium and 11 more
- Volunteers
- 12,046 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human, Pregnancy
Flucelvax (TIVc or QIVc) Pregnancy Registry
The study is a population based prospective cohort study designed to collect data on pregnancy outcomes and events of interest among women immunized with the TIVc or QIVc vaccine during pregnancy.
- Conditions
- Influenza, Human, Pregnancy, Birth Defect
- Trial name
- NCT03438487
- Testing
- Flucelvax Trivalent Influenza Vaccine, Flucelvax Quadrivalent Influenza Vaccine
- Where
- United States
- Volunteers
- 692 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza, Human
Enhanced Safety Surveillance of GlaxoSmithKline's (GSK's) Quadrivalent Seasonal Influenza Vaccines During the 2018/19 Influenza Season
The purpose of this study is to comply with the European Medicines Agency (EMA) guidance on enhanced safety surveillance for seasonal influenza vaccines in the European Union (EU) and aims to assess adverse events of interest…
- Trial name
- NCT03688620
- Testing
- Passive enhanced safety surveillance
- Where
- 9 sites in Belgium, Germany and 1 more
- Volunteers
- 1,060 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Preventive Medicine
Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI
The objective of this study is to obtain additional data on the efficacy and safety of 12-week course of therapy with Anaferon for children for prevention of influenza and other acute respiratory viral infections in children…
- Trial name
- NCT03301155
- Testing
- Anaferon for children
- Where
- 33 sites in Russia, Uzbekistan
- Volunteers
- 1,036 people, healthy volunteers welcome
- Sponsor
- Materia Medica Holding
Asthma
Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma
This is a randomized, double-blind, parallel group, placebo-controlled study designed to investigate the potential effect of a fixed dose of benralizumab administered subcutaneously (SC) on antibody responses following seasonal…
- Trial name
- ALIZE (NCT02814643)
- Testing
- Benralizumab, Seasonal influenza virus vaccine
- Where
- 24 sites in United States
- Volunteers
- 103 people
- Sponsor
- AstraZeneca
Prophylaxis of Avian Influenza
Immunogenicity, Safety and Tolerability of Two Doses of a Pre-pandemic Influenza Vaccine in Participants Aged 6 Months to 17 Years
Evaluate the immune response and reactogenicity of H5N1 vaccination in subjects aged 6 months to 17 years compared to seasonal flu vaccination
- Trial name
- NCT00537524
- Testing
- H5N1 Influenza Vaccine
- Where
- Finland
- Volunteers
- 471 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Novel 2009 Influenza H1N1, Influenza, Human
Tolerability and Immunogenicity Study of FLUVAL P H1N1 Flu Vaccine of Omninvest in Children and Adolescents
This is a single-blind, reference drug controlled study to assess safety and tolerability of FLUVAL P H1N1 monovalent influenza vaccine (whole virus, inactivated, adjuvanted with alumn phosphate gel) containing 6 mcgHA per 0.5mL…
- Trial name
- NCT01407978
- Testing
- Vaccination with Fluval P monovalent influenza vaccine, Vaccination with Fluval AB, Vaccination with Fluval AB Novo
- Where
- Hungary
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Fluart Innovative Vaccine Ltd, Hungary
Seasonal Influenza
Phase I Clinical Trial of Trivalent Inactivated Split Influenza Virus Vaccine (MDCK Cell)
This study is a phase I, randomized, double-blind, placebo and active comparator-controlled clinical trial to evaluate the safety and immunogenicity of a trivalent split influenza virus vaccine (MDCK cell) developed by Sinovac…
- Trial name
- NCT07889193
- Testing
- Cell-based Trivalent Split Influenza Virus Vaccine (cTIV), Egg-based Trivalent Split Influenza Virus Vaccine (eTIV)
- Where
- China
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd